Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-13T04:38:27.641Z Has data issue: false hasContentIssue false
  • English
  • Français

Yes, industry influence is excessive

Published online by Cambridge University Press:  22 August 2007

Amit A. Shah  and
Thomas E. Finucane
Amit A. Shah
Affiliation:
Assistant Professor, Section of Geriatric Medicine, University of Texas-Southwestern, Dallas TX, U.S.A. Email: Amit.Shah@UTSouthwestern.edu
Thomas E. Finucane
Affiliation:
Professor, Division of Geriatric Medicine, John Hopkins University, Baltimore MD, U.S.A. Email: tfinucan@jhmi.edu
Get access Rights & Permissions [Opens in a new window]

Extract

The pharmaceutical industry has made significant contributions to the field of geriatric psychiatry. Drug treatment has improved the quality of life for many vulnerable patients suffering from burdensome psychogeriatric syndromes. We do not dispute here the contributions of the pharmaceutical industry to patient care. Rather, we describe how the industry, driven by the need to produce profits, has implemented conscious strategies to promote the prescribing and thus the sales of drugs, without regard to patients' best interests. The industry has influenced the conduct and publication of research, and the promotion of drugs to physicians and patients, for purely marketing purposes.

Type
For Debate
Information
International Psychogeriatrics , Volume 19 , Issue 6 , December 2007 , pp. 1004 - 1010
Copyright
Copyright © International Psychogeriatric Association 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)